Clinical Trial Update: A Study to Examine the Efficacy and Safety of Meridia® (Sibutramine Hydrochloride) in Binge-Eating Disorder [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating Meridia (sibutramine hydrochloride) for binge-eating disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Binge Eating Disorder
• Obesity

Drugs mentioned

• Meridia (sibutramine)

Snippet

Sponsor: Abbott | Conditions: Binge Eating Disorder, Obesity | Phase 3 | Status: COMPLETED